Latest News & Updates

Breaking News

  • 6 hours ago

  • Simantini Singh Deo

Halda Therapeutics To Be Acquired By Johnson & Johnson For $3.05B, Backed By Promising HLD-0915 Phase 1/2 Data In Advanced Prostate Cancer
Breaking News
Clearmind Medicine Seeks Israeli Patent For Novel Neuroplastogen Treatment Offering Depression Relief Without Hallucinogenic Effects

Simantini Singh Deo

Other trending news you may like to read

Halda Therapeutics To Be Acquired By Johnson & Johnson For $3.05B, Backed By Promising HLD-0915 Phase 1/2 Data In Advanced Prostate Cancer

J&J to acquire Halda Therapeutics for $3.05B, advancing HLD-0915 and the company’s RIPTAC platform for metastatic prostate cancer.

Simantini Singh Deo

Pharma Now

Clearmind Medicine Seeks Israeli Patent For Novel Neuroplastogen Treatment Offering Depression Relief Without Hallucinogenic Effects

Clearmind files a new patent in Israel for an MEAI–PEA combination therapy aimed at advancing innovative depression treatments.

Simantini Singh Deo

Pharma Now

Apollomics Board Expands With Appointment Of Dr. Ya-Chi (Claudia) Huang; Strengthens Audit And Corporate Governance Committees

Apollomics appoints Dr. Ya-Chi Huang to its Board and key committees following the resignation of Po-Jen Hsueh.

Simantini Singh Deo

Pharma Now

FDA Supports Dewpoint Therapeutics’ DPTX3186 With Fast Track Designation For Gastric Cancer Treatment

FDA grants Fast Track status to Dewpoint’s DPTX3186, an oral condensate modulator targeting Wnt/β-catenin for gastric cancer.

Simantini Singh Deo

Pharma Now